指南与共识支持与姑息治疗

转移灶导向立体定向体部放疗联合靶向治疗或免疫治疗:EORTC-ESTRO OligoCare联盟的系统综述与共识建议

Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.
指南 / 共识 · Lancet Oncol · 2023-01-01

该系统综述与共识由EORTC-ESTRO OligoCare联盟制定,通过系统文献综述识别转移灶导向SBRT联合靶向治疗或免疫治疗的毒性特征,并基于此在28名跨学科专家中进行国际德尔菲共识流程,旨在为转移性或寡转移性癌症患者安全联合SBRT与靶向治疗或免疫治疗提供最佳证据,指导当前临床实践和未来临床试验设计。

要点

  • 系统综述总结了转移灶导向SBRT联合靶向治疗或免疫治疗的毒性特征,为共识提供依据。
  • 28名ESTRO和EORTC OligoCare联盟跨学科专家参与德尔菲共识,探讨风险缓解策略、治疗中断需求与时长及放疗剂量分割调整。
  • 共识旨在指导转移性或寡转移性癌症患者安全联合SBRT与靶向治疗或免疫治疗的临床实践及未来试验设计。

核心结论

  • 系统综述与共识流程汇总了转移灶导向SBRT联合靶向治疗或免疫治疗安全联合的最佳可用证据,旨在指导当前临床实践和未来临床试验设计。

研究设计与样本

  • 系统文献综述识别转移灶导向SBRT联合靶向治疗或免疫治疗的毒性特征,并以此为基础进行国际德尔菲共识流程。
  • 共识流程由28名欧洲放射治疗与肿瘤学会(ESTRO)和欧洲癌症研究与治疗组织(EORTC)OligoCare联盟的跨学科专家参与。

主要发现

  • 系统综述识别了转移灶导向SBRT联合靶向治疗或免疫治疗的毒性特征。
  • 德尔菲共识探讨了风险缓解策略、SBRT前后中断靶向治疗或免疫治疗的需求与时长以及放疗剂量分割的潜在调整。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Kroeze SGC, Pavic M, Stellamans K, et al. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium. Lancet Oncol. 2023. PMID: 36858728. doi:10.1016/S1470-2045(22)00752-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。